Dr. Shelley Boyd

Dr Shelley Boyd is a Retina Specialist and Clinician-Scientist who is dedicated to helping patients with Age Related Macular Degeneration (AMD). After graduate studies in molecular neurobiology, she trained in Medicine and Ophthalmology at the University of Toronto and followed with fellowships in Medical Retina at Moorfields Eye Hospital (London, UK) and in Cell Biology at the Scripps Research Institute (La Jolla, California). Specializing in diseases of blood vessels, Dr. Boyd then headed the global research and translational programs at the Novartis Pharmaceuticals (Basel, Switzerland) in the early development of Ranabizumab (Lucentis), a leading treatment for exudative (wet) AMD. On returning to Canada, Dr. Boyd established a “High Risk Dry AMD Clinic” at St Michael’s Hospital (Toronto) where she translated novel imaging methods and advanced image analytics from her lab to the clinical research setting.  She is the founding CEO of two biotechnology companies, Translatum Medicus inc and Tracery Ophthalmics inc, that are focused on drug development and biomarker development for dry AMD.